No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD
WEDNESDAY, July 21, 2021 -- For patients with stage 4 chronic kidney disease (CKD), a similar pattern of reduced kidney, cardiovascular, and mortality risks is seen with dapagliflozin versus placebo, with no evidence of increased risks, according to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Dapagliflozin | Forxiga | Heart | Pharmaceuticals | Urology & Nephrology